Latest Ratios: P/E Ratio 25.3x · EV/EBITDA 12.2x · ROE 153.6%. (2001–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $11.9B | $8.3B | $6.2B | $5.0B | $8.0B | $5.9B | $6.0B | $2.6B | $2.1B | $2.8B | $1.3B |
| Enterprise Value | $13.9B | $10.3B | $7.6B | $6.3B | $9.3B | $6.7B | $6.3B | $2.8B | $2.2B | $2.9B | $1.4B |
| P/E Ratio → | 25.33 | 26.29 | 13.94 | 17.60 | 39.51 | 14.68 | 46.93 | — | — | 45.02 | — |
| P/S Ratio | 6.60 | 5.97 | 6.09 | 5.98 | 12.12 | 13.31 | 22.58 | 13.06 | 13.83 | 8.90 | 8.62 |
| P/B Ratio | 254.51 | 170.83 | 17.01 | 59.18 | 47.12 | 29.97 | 40.00 | 27.89 | 8.44 | 13.52 | — |
| P/FCF | 13.43 | 12.94 | 13.21 | 13.29 | 34.00 | 19.81 | 114.11 | — | — | 21.23 | — |
| P/OCF | 18.25 | 12.80 | 12.92 | 12.76 | 33.32 | 19.71 | 108.95 | — | — | 21.02 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.41 | 7.46 | 7.65 | 14.05 | 15.02 | 23.51 | 14.50 | 14.28 | 9.01 | 9.64 |
| EV / EBITDA | 12.23 | 11.62 | 11.98 | 15.01 | 29.23 | 23.88 | 42.64 | — | — | 34.28 | — |
| EV / EBIT | 17.32 | 21.34 | 13.17 | 17.27 | 34.88 | 26.01 | 42.03 | — | — | 35.20 | — |
| EV / FCF | — | 16.05 | 16.18 | 16.99 | 39.41 | 22.35 | 118.82 | — | — | 21.49 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.6% | 83.6% | 84.3% | 76.8% | 78.9% | 81.6% | 83.8% | 76.8% | 93.3% | 90.2% | 77.4% |
| Operating Margin | 57.5% | 57.5% | 54.3% | 40.7% | 40.5% | 62.2% | 53.9% | -34.5% | -45.7% | 25.6% | -56.7% |
| Net Profit Margin | 22.7% | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | 48.2% | -36.9% | -52.9% | 19.9% | -70.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 153.6% | 153.6% | 198.4% | 222.1% | 110.2% | 231.4% | 106.3% | -42.4% | -35.1% | 71.6% | -1959.0% |
| ROA | 13.8% | 13.8% | 23.4% | 15.8% | 13.7% | 47.8% | 22.5% | -14.4% | -16.7% | 16.1% | -46.5% |
| ROIC | 31.6% | 31.6% | 25.7% | 17.4% | 16.7% | 30.5% | 27.9% | -14.7% | -18.6% | 33.8% | -74.8% |
| ROCE | 37.6% | 37.6% | 31.1% | 20.3% | 19.8% | 48.2% | 45.2% | -17.5% | -20.4% | 27.2% | -51.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 43.89 | 43.89 | 4.14 | 17.89 | 8.87 | 4.45 | 2.63 | 4.39 | 0.51 | 0.97 | — |
| Debt / EBITDA | 2.41 | 2.41 | 2.38 | 3.55 | 4.75 | 3.14 | 2.69 | — | — | 2.43 | — |
| Net Debt / Equity | — | 41.15 | 3.82 | 16.48 | 7.49 | 3.85 | 1.65 | 3.08 | 0.28 | 0.16 | — |
| Net Debt / EBITDA | 2.26 | 2.26 | 2.20 | 3.27 | 4.01 | 2.72 | 1.69 | — | — | 0.40 | — |
| Debt / FCF | — | 3.12 | 2.97 | 3.70 | 5.41 | 2.54 | 4.71 | — | — | 0.25 | — |
| Interest Coverage | 26.76 | 26.76 | 31.79 | 19.57 | 15.69 | 34.02 | 7.35 | -5.21 | -3.84 | 3.68 | -4.10 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.66 | 4.66 | 7.80 | 6.64 | 5.65 | 7.91 | 1.32 | 6.35 | 2.86 | 3.89 | 4.70 |
| Quick Ratio | 3.66 | 3.66 | 6.78 | 5.50 | 4.88 | 7.45 | 1.17 | 6.00 | 2.71 | 3.85 | 4.43 |
| Cash Ratio | 0.81 | 0.81 | 4.29 | 2.99 | 2.77 | 6.32 | 0.87 | 4.92 | 2.37 | 3.57 | 3.76 |
| Asset Turnover | — | 0.55 | 0.49 | 0.48 | 0.36 | 0.40 | 0.46 | 0.35 | 0.34 | 0.61 | 0.56 |
| Inventory Turnover | 1.30 | 1.30 | 1.12 | 1.51 | 1.39 | 1.51 | 0.71 | 1.55 | 0.45 | 6.05 | 2.27 |
| Days Sales Outstanding | — | 115.33 | 110.89 | 103.09 | 127.77 | 74.90 | 133.30 | 110.70 | 72.12 | 25.52 | 39.02 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.9% | 3.8% | 7.2% | 5.7% | 2.5% | 6.8% | 2.1% | — | — | 2.2% | — |
| FCF Yield | 7.4% | 7.7% | 7.6% | 7.5% | 2.9% | 5.0% | 0.9% | — | — | 4.7% | — |
| Buyback Yield | 2.9% | 4.1% | 4.0% | 8.1% | 2.5% | 5.9% | 2.5% | 7.8% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 2.9% | 4.1% | 4.0% | 8.1% | 2.5% | 5.9% | 2.5% | 7.8% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $124M | $129M | $134M | $141M | $147M | $141M | $144M | $144M | $139M | $128M |
Includes 30+ ratios · 25 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HALO stock.
Halozyme Therapeutics, Inc.'s current P/E ratio is 25.3x. The historical average is 29.1x. This places it at the 43th percentile of its historical range.
Halozyme Therapeutics, Inc.'s current EV/EBITDA is 12.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.1x.
Halozyme Therapeutics, Inc.'s return on equity (ROE) is 153.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -32.3%.
Based on historical data, Halozyme Therapeutics, Inc. is trading at a P/E of 25.3x. This is at the 43th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Halozyme Therapeutics, Inc. has 83.6% gross margin and 57.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Halozyme Therapeutics, Inc.'s Debt/EBITDA ratio is 2.4x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
Negative equity and rising leverage
Metrics are mathematically derived from official filings.
Trailing Multiples Overstate Forward Earnings Discount
Based on reported figures, HALO trades at 25.7x trailing P/E but only 11.8x forward P/E, a gap that suggests consensus expects earnings to roughly double as revenue momentum continues.
The compression from trailing to forward P/E implies the market is pricing in a meaningful earnings step-up rather than paying for current reported profit, which was distorted by the 2025Q4 net loss. The PEG of 1.12 sits near the fair-value threshold, suggesting the growth premium is roughly priced in, though investors should monitor whether forward estimates hold given quarterly volatility. Against peers, HALO's EV/EBITDA of 12.4x is reasonable relative to ALNY at 20.3x and EXEL at 16.9x, but the 258x price-to-book reflects a shrinking equity base and offers little useful valuation signal.
Operating Margins Sustained Above Fifty Percent
As reported in financial statements, HALO's operating margin reached 59.8% in 2026Q3 with gross margin at 83.3%, levels that sit well above most of the peer set and indicate a highly scalable royalty-style revenue model.
Operating margin has held in a 49% to 62% band across the ten quarters, implying that incremental revenue is converting to operating income at a high rate with SG&A largely fixed. Net margin of 50.1% in the latest quarter is consistent with this, although the 2025Q4 negative net margin of -31.3% reflects non-operating or tax items rather than deteriorating operations, making operating margin a more reliable gauge of earning power. The durability of these margins warrants further investigation given the concentration of the revenue base.
Returns Recovering From Mid-Cycle Trough
According to recent reported figures, HALO's ROIC rose from 5.6% in 2024Q2 to 10.3% in 2026Q3, a recovery that appears driven mainly by margin expansion rather than improved capital efficiency.
ROE readings are heavily distorted by a shrinking equity base, with the 126.6% figure in 2026Q2 and the negative equity implied in 2026Q3 making ROE not meaningful as a compounding measure. ROIC is the more reliable indicator here, and its improvement from the 2024 trough suggests returns are recovering, though at roughly 10% they remain modest relative to ALNY's 93.2% and EXEL's 32.1%. Investors should monitor whether ROIC can be sustained as buybacks reduce equity and alter the invested capital base.
Debt Expansion Outpaces Equity Cushion
Based on reported figures, HALO's debt-to-EBITDA ratio stands at 9.9x in 2026Q3 against interest coverage of 49.1x, a combination that suggests debt service remains comfortable on current earnings even as the balance sheet grows more leveraged.
Total debt rising from roughly $1.5B to $3.3B while equity turned negative points to a capital structure increasingly funded by liabilities, which may indicate reduced flexibility should earnings weaken. Interest coverage above 30x in most quarters implies current operating income covers financing costs comfortably, yet the D/EBITDA trajectory from 3.1x in 2025Q1 to 9.9x suggests leverage has risen faster than cash generation. Refinancing terms and covenant headroom are not disclosed in the supplied data, so these conclusions should be treated as analytical inference warranting further review.
Trailing Margins Misread as Earnings Durability
The ratio most commonly misapplied to HALO is operating margin treated as a durable earnings measure, since the 59.8% figure may reflect concentrated royalty streams rather than a broadly diversified and repeatable profit base.
Investors often read sustained margins above 50% as evidence of a defensible franchise, but this can obscure dependence on a narrow set of licensed products and milestone timing that drives quarterly volatility. A better complement is free cash flow margin on a trailing twelve-month basis combined with revenue concentration by product, which would show whether the cash output is recurring. Given that net margin swung from 47.8% to -31.3% within two quarters, operating margin alone appears insufficient as a guide to underlying earning power.